TLIS - Talis shares rise after FDA EUA for Talis One COVID-19 Test System

Talis Biomedical (NASDAQ:TLIS) announces that the U.S. FDA has granted Emergency Use Authorization (EUA) for its Talis One COVID-19 Test System - a nucleic acid amplification test (NAAT). Shares up more than 8% premarket. The test runs on an integrated system that includes a compact instrument, self-contained, single-use test cartridges and software for reporting results. In a clinical study, the Talis One COVID-19 Test System demonstrated 100% concordance with the comparator test results, including both the positive and negative percent agreements, the company said.

For further details see:

Talis shares rise after FDA EUA for Talis One COVID-19 Test System